[{"indications": "Indications\u00a0advanced prostate cancer; other indications\r\n(section 6.7.2)", "name": "BUSERELIN - GONADORELIN ANALOGUES AND GONADOTROPHIN-RELEASING HORMONE ANTAGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Gonadorelin analogues"], "cautions": "Cautions\u00a0diabetes, hypertension, depression; see\r\nalso notes above", "side-effects": "Side-effects\u00a0\n(From Gonadorelin analogues: British National Formulary)\nSide-effects\u00a0The gonadorelin analogues cause side-effects similar to the menopause in women and orchidectomy in men and include hot flushes and sweating, sexual dysfunction, vaginal dryness or bleeding, and gynaecomastia or changes in breast size. Signs and symptoms of prostate or breast cancer may worsen initially (managed in prostate cancer with anti-androgens, see above). Other side-effects include hypersensitivity reactions (rashes, pruritus, asthma, and rarely anaphylaxis), injection site reactions (see Cautions), headache (rarely migraine), visual disturbances, dizziness, arthralgia and possibly myalgia, hair loss, peripheral oedema, gastro-intestinal disturbances, weight changes, sleep disorders, and mood changes.; worsening\r\nhypertension, palpitation, glucose intolerance,\r\naltered blood lipids, thrombocytopenia, leucopenia, nervousness, fatigue,\r\nmemory and concentration disturbances, anxiety, increased thirst,\r\nhearing disorders, musculoskeletal pain; nasal irritation, nose bleeds\r\nand altered sense of taste and smell (spray formulation only)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4824.htm", "doses": ["By subcutaneous injection, 500\u00a0micrograms\r\nevery 8 hours for 7 days, then intranasally, 1 spray\r\ninto each nostril 6 times daily (see also notes above)", "Avoid use of nasal decongestants\r\nbefore and for at least 30 minutes after treatment."]}, {"indications": "Indications\u00a0see under Dose; prostate\r\ncancer (section 8.3.4.2)", "name": "BUSERELIN - DRUGS AFFECTING GONADOTROPHINS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.2 Drugs affecting gonadotrophins", "Gonadorelin analogues", "BUSERELIN"], "cautions": "Cautions\u00a0\n(From Gonadorelin analogues: British National Formulary)\nCautions\u00a0Non-hormonal, barrier methods of contraception should be used during entire treatment period with gonadorelin analogues; also use with caution in patients with metabolic bone disease because decrease in bone mineral density can occur.; polycystic ovarian disease, depression, hypertension, diabetes", "side-effects": "Side-effects\u00a0see notes above; initially withdrawal bleeding\r\nand subsequently breakthrough bleeding, leucorrhoea; nausea, vomiting,\r\nconstipation, diarrhoea; anxiety, memory and concentration disturbances,\r\nsleep disturbances, nervousness, dizziness, drowsiness; breast tenderness,\r\nlactation; abdominal pain; fatigue; increased thirst, changes in appetite;\r\nacne, dry skin, splitting nails, dry eyes; altered blood lipids, leucopenia,\r\nthrombocytopenia; hearing disturbances; reduced glucose tolerance", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4470.htm", "doses": ["Endometriosis, intranasally, 300\u00a0micrograms\r\n(one 150-microgram spray in each nostril) 3 times daily (starting\r\non days 1 or 2 of menstruation); max. duration of treatment 6 months\r\n(do not repeat)", "Pituitary desensitisation before induction of ovulation\r\nby gonadotrophins for in vitro fertilisation (under\r\nspecialist supervision), by subcutaneous injection,\r\n200\u2013500\u00a0micrograms daily given as a single injection (occasionally\r\nup to 500\u00a0micrograms twice daily may be needed) starting in early\r\nfollicular phase (day 1) or, after exclusion of pregnancy,\r\nin midluteal phase (day 21) and continued until down-regulation achieved\r\n(usually about 1\u20133 weeks) then maintained during gonadotrophin administration\r\n(stopping gonadotrophin and buserelin on administration\r\nof chorionic gonadotrophin at appropriate stage\r\nof follicular development)", "Intranasally, 150\u00a0micrograms (one spray in one\r\nnostril) 4 times daily during waking hours (occasionally up to 300\u00a0micrograms\r\n4 times daily may be needed) starting in early follicular phase (day\r\n1) or, after exclusion of pregnancy, in midluteal\r\nphase (day 21) and continued until down-regulation achieved (usually\r\nabout 2\u20133 weeks) then maintained during gonadotrophin administration\r\n(stopping gonadotrophin and buserelin on administration\r\nof chorionic gonadotrophin at appropriate stage\r\nof follicular development)", "Avoid use of nasal decongestants before\r\nand for at least 30 minutes after treatment"], "pregnancy": "Pregnancy\u00a0\n(From Gonadorelin analogues: British National Formulary)\nGonadorelin analogues"}, {"indications": "Indications\u00a0advanced prostate cancer; other indications\r\n(section 6.7.2)", "name": "BUSERELIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Gonadorelin analogues"], "cautions": "Cautions\u00a0diabetes, hypertension, depression; see\r\nalso notes above", "side-effects": "Side-effects\u00a0\n(From Gonadorelin analogues: British National Formulary)\nSide-effects\u00a0The gonadorelin analogues cause side-effects similar to the menopause in women and orchidectomy in men and include hot flushes and sweating, sexual dysfunction, vaginal dryness or bleeding, and gynaecomastia or changes in breast size. Signs and symptoms of prostate or breast cancer may worsen initially (managed in prostate cancer with anti-androgens, see above). Other side-effects include hypersensitivity reactions (rashes, pruritus, asthma, and rarely anaphylaxis), injection site reactions (see Cautions), headache (rarely migraine), visual disturbances, dizziness, arthralgia and possibly myalgia, hair loss, peripheral oedema, gastro-intestinal disturbances, weight changes, sleep disorders, and mood changes.; worsening\r\nhypertension, palpitation, glucose intolerance,\r\naltered blood lipids, thrombocytopenia, leucopenia, nervousness, fatigue,\r\nmemory and concentration disturbances, anxiety, increased thirst,\r\nhearing disorders, musculoskeletal pain; nasal irritation, nose bleeds\r\nand altered sense of taste and smell (spray formulation only)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4824.htm", "doses": ["By subcutaneous injection, 500\u00a0micrograms\r\nevery 8 hours for 7 days, then intranasally, 1 spray\r\ninto each nostril 6 times daily (see also notes above)", "Avoid use of nasal decongestants\r\nbefore and for at least 30 minutes after treatment."]}]